Miller C M, Gondolesi G E, Florman S, Matsumoto C, Muñoz L, Yoshizumi T, Artis T, Fishbein T M, Sheiner P A, Kim-Schluger L, Schiano T, Shneider B L, Emre S, Schwartz M E
Recanati/Miller Transplantation Institute, Mount Sinai Hospital, Mount Sinai School of Medicine, New York, New York 10029, USA.
Ann Surg. 2001 Sep;234(3):301-11; discussion 311-2. doi: 10.1097/00000658-200109000-00004.
To summarize the evolution of a living donor liver transplant program and the authors' experience with 109 cases.
The authors' institution began to offer living donor liver transplants to children in 1993 and to adults in 1998.
Donors were healthy, ages 18 to 60 years, related or unrelated, and ABO-compatible (except in one case). Donor evaluation was thorough. Liver biopsy was performed for abnormal lipid profiles or a history of significant alcohol use, a body mass index more than 28, or suspected steatosis. Imaging studies included angiography, computed tomography, endoscopic retrograde cholangiopancreatography, and magnetic resonance imaging. Recipient evaluation and management were the same as for cadaveric transplant.
After ABO screening, 136 potential donors were evaluated for 113 recipients; 23 donors withdrew for medical or personal reasons. Four donor surgeries were aborted; 109 transplants were performed. Fifty children (18 years or younger) received 47 left lateral segments and 3 left lobes; 59 adults received 50 right lobes and 9 left lobes. The average donor hospital stay was 6 days. Two donors each required one unit of banked blood. Right lobe donors had three bile leaks from the cut surface of the liver; all resolved. Another right lobe donor had prolonged hyperbilirubinemia. Three donors had small bowel obstructions; two required operation. All donors are alive and well. The most common indications for transplant were biliary atresia in children (56%) and hepatitis C in adults (40%); 35.6% of adults had hepatocellular carcinoma. Biliary reconstructions in all children and 44 adults were with a Roux-en-Y hepaticojejunostomy; 15 adults had duct-to-duct anastomoses. The incidence of major vascular complications was 12% in children and 11.8% in adult recipients. Children had three bile leaks (6%) and six (12%) biliary strictures. Adult patients had 14 (23.7%) bile leaks and 4 (6.8%) biliary strictures. Patient and graft survival rates were 87.6% and 81%, respectively, at 1 year and 75.1% and 69.6% at 5 years. In children, patient and graft survival rates were 89.9% and 85.8%, respectively, at 1 year and 80.9% and 78% at 5 years. In adults, patient and graft survival rates were 85.6% and 77%, respectively, at 1 year.
Living donor liver transplantation has become an important option for our patients and has dramatically changed our approach to patients with liver failure. The donor surgery is safe and can be done with minimal complications. We expect that living donor liver transplants will represent more than 50% of our transplants within 3 years.
总结活体肝移植项目的发展历程及作者对109例病例的经验。
作者所在机构于1993年开始为儿童提供活体肝移植,1998年开始为成人提供。
供体健康,年龄在18至60岁之间,有血缘关系或无血缘关系,且ABO血型相容(1例除外)。对供体进行了全面评估。对血脂异常、有大量饮酒史、体重指数超过28或疑似脂肪变性的供体进行肝活检。影像学检查包括血管造影、计算机断层扫描、内镜逆行胰胆管造影和磁共振成像。受体评估和管理与尸体移植相同。
经过ABO血型筛查,对113名受体评估了136名潜在供体;23名供体因医疗或个人原因退出。4例供体手术中止;实施了109例移植手术。50名儿童(18岁及以下)接受了47个左外侧叶和3个左叶;59名成人接受了50个右叶和9个左叶。供体平均住院时间为6天。两名供体各需要1单位库存血。右叶供体肝脏切面有3例胆漏;均已愈合。另一名右叶供体有持续性高胆红素血症。3名供体发生小肠梗阻;2名需要手术治疗。所有供体均存活且状况良好。最常见的移植适应证儿童为胆道闭锁(56%),成人为丙型肝炎(40%);35.6%的成人患有肝细胞癌。所有儿童和44名成人的胆道重建采用Roux-en-Y肝空肠吻合术;15名成人采用胆管对端吻合术。儿童主要血管并发症发生率为12%,成人受体为11.8%。儿童有3例胆漏(6%)和6例(12%)胆道狭窄。成人患者有14例(23.7%)胆漏和4例(6.8%)胆道狭窄。患者和移植物1年生存率分别为87.6%和81%,5年生存率分别为75.1%和69.6%。儿童患者和移植物1年生存率分别为89.9%和85.8%,5年生存率分别为80.9%和78%。成人患者和移植物1年生存率分别为85.6%和77%。
活体肝移植已成为我们患者的重要选择,并极大地改变了我们对肝衰竭患者的治疗方法。供体手术安全,并发症极少。我们预计3年内活体肝移植将占我们移植手术的50%以上。